智雲健康(09955.HK)公開發售獲超額認購7.89倍 預計7月6日掛牌上市
格隆匯7月5日丨智雲健康(09955.HK)發佈公吿，公司全球發售1900萬股股份，其中香港發售股份190萬股，國際發售股份1710萬股，另有15%超額配股權；發售價已釐定為每股發售股份30.50港元，每手買賣單位100股；摩根士丹利及摩根大通為聯席保薦人；預期股份將於2022年7月6日於聯交所主板掛牌上市。
香港發售股份已獲輕微超額認購，合共已接獲8,629份有效申請，認購合共1498.85萬股發售股份，相當於香港公開發售項下初步可供認購香港發售股份總數約7.89倍。 國際發售項下初步提呈發售的發售股份已獲輕微超額認購，相當於國際發售項下初步可供認購發售股份總數的約2.15倍。根據與基石投資者的基石投資協議，基石投資者認購的發售股份數目現已釐定。Sanofi Foreign Participations B.V.已認購386.06萬股、代表Harvest Great Bay Investment SP的Harvest International Premium Value (Secondary Market) Fund SPC已認購514.75萬股、揚子江（香港）有限公司已認購128.68萬股及Tasly International Capital Limited已認購128.68萬股，合共1158.17萬股發售股份。
假設並無行使超額配股權及並無根據股份激勵計劃發行股份，則按發售價每股30.50港元計算的估計全球發售所得款項淨額約為4.817億港元。集團擬將該等所得款項淨額約60%用於業務擴張，集團將繼續實施“醫院為先”戰略，擴大集團全國的醫院網絡。利用集團的醫院網絡與產業價值鏈上的更多行業參與者聯繫，並繼續加強和擴大集團的解決方案系列，以推動客户及用户參與；約25%預計將用於提高集團的醫學知識和技術能力，以加強集團在數字醫療行業的領導地位，並投資深化集團與行業參與者的聯繫，提供更好的醫療；約5%預計用於通過戰略伙伴關係、投資和收購其他業務來擴大集團的生態系統，以補充集團的有機成長戰略。集團計劃繼續提升集團在價值鏈上游和下游的地位，並有選擇地尋求聯盟和投資機會；及約10%的所得款項淨額預計將用於營運資金和一般公司用途。倘超額配股權獲悉數行使，集團將就行使超額配股權後將發行的285萬股額外發售股份收取額外所得款項淨額約8340萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
